The Controversies Surrounding Bevacizumab and Ranibizumab
Ee Vien Low, Faridah Aryani Md. Yusof
Advances in Research · pp. 334–340 · Published 24 Oct 2014
10.9734/AIR/2015/13322Abstract
Age-related macular degeneration (AMD) is a leading cause of visual impairment and blindness. Both bevacizumab and ranibizumab are anti-vascular endothelial growth factors used for treatment of AMD. However the use of bevacizumab remains controversial as it was not approved for intravitreal use although there were several head-to-head comparison trial that shows that it was non inferior to ranibizumab. Despite the status of off-label, intravitreal bevacizumab is being used worldwide as it is 30-50 times cheaper than intravitreal ranibizumab. The case of intravitreal bevacizumab illustrates the use of “not-me” drug and different countries responds differently to its use.
Cited by 0
No indexed citations yet.
Related research
- The Epidemiology and Type of Macular Disease Seen in a Teaching Hospital in South-West, Nigeria — shares topic coverage
- Tachyphylaxis to ranibizumab in the Treatment of Age-related Macular Degeneration — shares topic coverage
- The Effect of Required Injection Numbers during the First Year on the Clinical Course of Neovascular Age-related Macular Degeneration — shares topic coverage
- Assessment of Subfoveal Choroidal Thickness with SD-OCT in Eyes with Different Stages of Age-Related Macular Degeneration (AMD) — shares topic coverage
- Efficacy Analysis of Corneal Photo-vitrification (CPV) for Improved Vision of Age-related Macular Degeneration (AMD) Eyes — shares topic coverage
Article metrics
Real usage data collected on this platform.
0
Page views
0
PDF downloads
0
Outbound clicks
0
Citations
Views by country
Approximate, from request IP at view time — not citizenship or institution. Countries with fewer than 5 views are grouped as "Other".
No views recorded yet.
Traffic sources
Referring site, by host.
No traffic recorded yet.
Views and downloads exclude known bots/crawlers. Citations combines this platform's own DOI-resolved index with each external source's own reported total — see Cited by above for individually listed citing works. Last refreshed 0 seconds ago.